Clinical Trials Logo
  1. Home
  2. Sleep Problems
  3. NCT01903681

Assessment of the Pharmacokinetics of Circadin® in Children With Neurodevelopmental Disorders and Sleep Disturbances

Sleep Problems Clinical Trial

Official title:
Open Label, Single Ascending Dose, Cross-over Study to Assess the Pharmacokinetics of Circadin® (Prolonged-Release Melatonin) Mini Tablets in Children With Neurodevelopmental Disorders and Sleep Disturbances

Clinical Trial Summary

There is increasing evidence that chronic sleep disorders in children with autism spectrum disorder (ASD), Angelman Syndrome (AS) and Smith-Magenis syndrome (SMS) are associated with disturbed melatonin secretion and melatonin administration has been shown to be effective in these populations. For children who have difficulties swallowing a tablet, Neurim has developed an age-appropriate Melatonin formulation in the form of mini-tablets which have the same dissolution profile as the Circadin® tablets product, thus should produce the same melatonin concentration-time profile with the same effects. This study concerns the pharmacokinetic study.

The purpose of this study is to :

- Establish the 24 hour baseline profile of endogenous saliva melatonin concentrations and urine 6-SMT excretion in children aged 2 up to and including 17 years with neurodevelopmental disorders with sleep disturbances.

- Establish the concentration-time profile of saliva melatonin concentrations and 24 hour 6-SMT urine excretion after 2 and 10 mg Circadin® mini-tablets single dose administration in children aged 2 up to and including 17 years with neurodevelopmental disorders with sleep disturbances.

- Evaluate the adverse event profile after a single dose of 2 or 10 mg Circadin® mini-tablets in children aged 2 up to and including 17 years with neurodevelopmental disorders with sleep disturbances.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01903681
Study type Interventional
Source Neurim Pharmaceuticals Ltd.
Contact
Status Completed
Phase Phase 1
Start date March 2013
Completion date April 2014
View Details
See also
  Status Clinical Trial Phase
Completed NCT02370173 - A Non-Pharmacological Method for Enhancing Sleep in PTSD N/A
Completed NCT00691080 - Understanding Sleep Problems in Children With Autism Spectrum Disorder Phase 2/Phase 3
Recruiting NCT04633434 - Evaluation Study of Talk Parenting Skills N/A
Completed NCT01064544 - Study on Hemodialysis: Illumination Effects Phase 3
Completed NCT02670694 - Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW N/A
Completed NCT00877162 - The Rocky Sleep Study N/A
Completed NCT00133055 - Parenting Matters: Helping Parents With Young Children Phase 2
Completed NCT01764074 - Brief Sleep Intervention for Bipolar Disorder N/A
Recruiting NCT05072548 - The ABCs of SLEEPING: Effectiveness Study N/A
Completed NCT01764035 - Mindfulness Therapy on Disrupted Sleep in Bipolar Disorder N/A
Completed NCT01534338 - Effect of Mindfulness Training on Sleep and Inflammation Among Older Adults With Sleep Problems Phase 1/Phase 2
Not yet recruiting NCT06249217 - Good Nights Sleep Program to Improve Child and Family Sleep Phase 1/Phase 2
Completed NCT02374918 - Bright Light Therapy for Treatment of Sleep Problems Following Mild Traumatic Brain Injury N/A
Completed NCT01747811 - Effects of Bright Light Therapy in Mild Traumatic Brain Injury N/A
Completed NCT04413188 - A Warm Foot Bath, Sleep Quality and Comfort Level N/A
Completed NCT00388661 - Melatonin and Quality of Life in Dialysis Patients Phase 3
Completed NCT00404456 - The Efficacy of Melatonin in Sleep Problems of Hemodialysis and Peritoneal Dialysis Patients Phase 3